Archives
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
As CP is a crucial player in centriole duplication it
2021-07-06
As CP110 is a crucial player in centriole duplication, it is intriguing to ask whether centriole duplication would also be affected in the absence of the CP110-stabilizing effects of USP33. Li et al.[4] found that USP33 depletion did not inhibit normal centriole duplication through loss of centriole
-
br Conclusions and future directions In
2021-07-06
Conclusions and future directions In recent years we saw major advances in our knowledge of H2A-DUB biology, with discovery of novel mammalian H2A-DUBs, better understanding of their biochemical properties, and development of several animal models to address their in vivo functions. However at pr
-
To explore the mechanism behind differential activation kine
2021-07-06
To explore the mechanism behind differential activation kinetics, Marcott et al. (2018) manipulate local dopamine dynamics. They show that differences in dopamine concentrations are not responsible for different D2R activation kinetics, since D2-IPSCs reach similar amplitudes at different rates in N
-
Tamoxifen is included in the treatment
2021-07-06
Tamoxifen is included in the treatment protocol of ER+ breast carcinoma patients routinely. Although tamoxifen improves patients' survival, unfortunately a large number of ER+ patients don't response to tamoxifen treatment (Yager and Davidson, 2006). Detection of molecular markers which could take a
-
Raloxifene HCl The first example of a broadly acting antivir
2021-07-06
The first example of a broadly-acting antiviral drug is ribavirin, a nucleoside analogue that was proposed to act directly at the level of the viral polymerase, although an indirect effect via inhibition of the host-cell IMP dehydrogenase and depletion of the GTP pool seems more plausible [9]. Anoth
-
br Additional CDKs with a role
2021-07-06
Additional CDKs with a role in cancer Small molecule CDK inhibitors The majority of protein kinase inhibitors developed to date are type I inhibitors: they bind at the ATP–binding site, are ATP-competitive and target the kinase in its active state; with the activation loop DFG motif in the ‘in
-
Today many strategies have been developed to
2021-07-06
Today, many strategies have been developed to enhance CXCR-4 receptor MK 571 sale on the cell surface, either by modifying the cell culture medium or by modifying the CXCR-4 gene in BMSCs to stimulate stem cell recruitment (Jiang et al., 2012, Liu et al., 2014b). For instance, the pre-conditioning
-
In summary A is a
2021-07-06
In summary, A-216546 is a potent, orally available endothelin receptor antagonist with a high selectivity for the endothelin ETA receptor. The potency and bioavailability of A-216546 suggest that it will have important utility for preclinical evaluation of the pathophysiology of the endothelin syste
-
Our comparison of all ER iso forms with ER immunostaining
2021-07-06
Our comparison of all ERα (iso)forms with ERβ immunostaining suggests that overall ERβ expression is lower than that of ERα isoforms. This contrasts the so far reported data for ERs in the lung, but is not a paradox; in pathology routine, ER positivity is defined stricto senso by nuclear WT ERs. As
-
The AURA trial was a phase I II study
2021-07-06
The AURA trial was a phase I/II study evaluating the safety, tolerability and activity of Osimertinib in patients with EGFR-mutated NSCLC progressing after a previous EGFR TKI. The phase I component of the study included a dose escalation part (Osimertinib 20mg to 240mg), using a rolling six design,
-
br Acknowledgements The authors are supported by National
2021-07-05
Acknowledgements The authors are supported by National Institutes of Health grants (CA162804, CA92584, and CA13499 to DJC and CA166677 to BPPC) and Cancer Prevention and Research Institute of Texas (RP110465 to DJC). The cellular response to DNA double-strand break (DSB) formation is an essent
-
br UVC induced DNA damage a model to study DNA
2021-07-05
UVC-induced DNA damage: a model to study DNA damage tolerance The UV components of sunlight that reaches the Earth surface are one of the most carcinogenic agents humans are exposed to, and the leading cause of skin cancer [4,12]. UV light causes different types of DNA damage through indirect and
-
As the first allotetraploid fish in the world
2021-07-05
As the first allotetraploid fish in the world, our lab selectively breed the allotetraploid hybrid fish (4nAT, 4n = 200) from the distant hybridization offspring F3 of female Red Crucian Carp (Carassius auratus red var., abbreviated as RCC, 2n = 100) and male Common Carp (Cyprinius carpio L., abbrev
-
PR-171 In the present study we combined activity based prote
2021-07-05
In the present study, we combined activity-based protein profiling, biochemical and genetic approaches to identify the PLCPs involved in the sphingolipid pathway leading to plant PCD. By using Arabidopsis PR-171 and leaves, we demonstrate that this sub-class of plant proteases is activated in respo
-
Introduction Cysteinyl leukotrienes CysLTs LTC LTD and LTE a
2021-07-05
Introduction Cysteinyl leukotrienes (CysLTs), LTC4, LTD4 and LTE4, are 5-lipoxygenase pathway metabolites of arachidonic SGI-1027 synthesis and deeply involved in bronchial asthma via activation of CysLT1 receptors [1], [2]. Specific CysLT1 receptor antagonists, including pranlukast [3], [4] and m
16157 records 634/1078 page Previous Next First page 上5页 631632633634635 下5页 Last page